A Phase 3 interventional study of CKD-501 0.5mg and Placebo in Type2 Diabetes, sponsored by Chong Kun Dang Pharmaceutical. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-08-22.
Sponsored by Chong Kun Dang Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. lobeglitazone · Diabetes Mellitus, Type 2.
Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 16th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 41 across the 23 interventional studies. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 3 most frequent:
Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.
64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical: 3 open now, 4 under way, none of them phase 3. Of 45 finished, 0 (0%) have results posted.
Among the 64 studies in Diabetes Mellitus, Type 2 by Chong Kun Dang Pharmaceutical, this one is the 3rd largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 3, and was the 19th registered.
Chong Kun Dang Pharmaceutical’s Diabetes Mellitus, Type 2 studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing lobeglitazone in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Chong Kun Dang Pharmaceutical’s 64 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to prove that the group treated with CKD-501 in combination added that the reduction of glycated hemoglobin superior to placebo treated group added in combination.
The aim of this phase 3 study was to evaluate the efficacy and safety of additional combined CKD-501 administration for 24 weeks in patient with type 2 diabetes who were nao adequately controlled for blood glucose by the combination of D150 and D759
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CKD-501 0.5mg
Drug: CKD-501 0.5mg
Placebo
Drug: Placebo
CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
Also known as: Lobeglitazone
Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
Change from baseline in Glycosylated Hemoglobin
Time frame: Baseline, 24weeks
Change from baseline in in Glycosylated Hemoglobin
Time frame: Baseline, 52weekes
Change from baseline in Fasting plasma glucose
Time frame: Baseline, 24weeks, 52weeks
HbA1c target achievement rate at 24weekes(HbA1c < 6.5%, 7%)
Time frame: Baseline, 24weeks
Change from baseline in Total Cholesterol
Time frame: Baseline, 24weeks, 52weeks
Evaluate safety of CKD-501 from number of participants with adverse events
Time frame: Baseline, 24weeks, 52weeks
Change from baseline in HOMA-IR(Homeostasis Model Assessment of Insulin Resistance)
Time frame: Baseline, 24weeks, 52weeks
Change from baseline in HOMA-β(Homeostasis Model Assessment of β-cell function)
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in QUICKI(Quantitative Insulin Check Index)
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in Triglycerides
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in LDL-Cholesterol
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in HDL-Cholesterol
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in non-HDL-Cholesterol
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in Small Dense LDL-Cholesterol
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in FFA(Free Fatty Acid)
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in Apo-B
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in Apo-CⅢ
Time frame: Baseline, 24 weeks, 52 weeks
Change from baseline in Apo-AⅠ
Time frame: Baseline, 24 weeks, 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2018 (actual). Primary completion is estimated for Apr 2021, 35 months after the start.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 35 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lobeglitazone
Chong Kun Dang Pharmaceutical →